A researcher as well as a surgical oncologist, Dr. Bold is an expert in pancreatic and hepatobiliary cancers, breast cancer and the application of minimally invasive surgical techniques to the patient with cancer. He oversees an active basic-science laboratory investigating mechanisms of resistance to traditional chemotherapy as well as testing new treatments for detecting and treating cancer. He has published extensively in the areas of apoptosis, metastasis, and the cellular biology of pancreatic and lung cancers. He also is the principal investigator for the American College of Surgeons Oncology Group (ACOSOG) at UC Davis and is an integral member of the Clinical Trials Group at the UC Davis Cancer Center.
Dr. Bold has implemented a variety of minimally invasive techniques used in the surgical treatment of patients with various tumors (both benign and malignant). This includes the sentinel lymph-node biopsy procedure for women with breast cancer and a variety of laparoscopic procedures for abdominal tumors, including laparoscopic adrenalectomy, splenectomy and pancreatectomy.
4501 X St.
Sacramento, CA 95817
Palo Alto, California
University of Texas Medical Branch
UC Davis-East Bay
Oakland , California
American Association for Cancer Research
American College of Surgeons
Association of Academic Surgery
North American Surgical Oncology Group
Pacific Coast Surgical Association
Sacramento Surgical Society
Society of Surgical Oncology
Society of University Surgeons
The Pancreas Club
The Society for Surgery of the Alimentary Tract
Honors and Awards:
Outstanding Faculty Member in a Teaching Capacity, UC Davis Medical Center, Department of Surgery, 2003
Christine and Helen Landgraf Memorial Award for Cancer Research, 2000
Center Liaison Physician for the American College of Surgeons Commission on Cancer from UC Davis Medical Center, 2000
James Ewing Oncology Fellowship, 1999
Franklin H. Martin Faculty Research Fellowship, 1999
Marvin M. Romsdahl Clinical Excellence Award, M.D.Anderson Center, 1998
Select Recent Publications:
Martinez SR, Tseng WH, Canter RJ, Chen AM, Chen SL, Bold RJ. Do radiation use disparities influence survival in patients with advanced breast cancer? Cancer. 2012 Jan 1;118(1):196-204. doi: 10.1002/cncr.26231. Epub 2011 Jun 20.
Vanderveen KA, Canter RJ, Yin D, Cress RD, Bold RJ. Factors affecting treatment delivery and outcomes of patients with early-stage pancreatic adenocarcinoma. Pancreas. 2011 Apr;40(3):480-2.
Tseng WH, Jin L, Canter RJ, Martinez SR, Khatri VP, Gauvin J, Bold RJ, Wisner D, Taylor S, Chen SL. Surgical resident involvement is safe for common elective general surgery procedures. J Am Coll Surg. 2011 Jul;213(1):19-26; discussion 26-8. Epub 2011 Apr 13.
Tseng WH, Yang X, Wang H, Martinez SR, Chen SL, Meyers FJ, Bold RJ, Canter RJ. Nomogram to predict risk of 30-day morbidity and mortality for patients with disseminated malignancy undergoing surgical intervention. Ann Surg. 2011 Aug;254(2):333-8.
Tseng WH, Canter RJ, Bold RJ. Perioperative outcomes for open distal pancreatectomy: current benchmarks for comparison. J Gastrointest Surg. 2011 Nov;15(11):2053-8. Epub 2011 Sep 22.
Coates JM, Galante JM, Bold RJ. Cancer therapy beyond apoptosis: autophagy and anoikis as mechanisms of cell death. J Surg Res. 2010 Dec;164(2):301-8. Epub 2009 Aug 7. Review.
Muilenburg DJ, Coates JM, Virudachalam S, Bold RJ. Targeting Bcl-2-mediated cell death as a novel therapy in pancreatic cancer. J Surg Res. 2010 Oct;163(2):276-81. Epub 2010 Mar 12.
Martinez SR, Beal SH, Chen SL, Canter RJ, Khatri VP, Chen A, Bold RJ. Disparities in the use of radiation therapy in patients with local-regionally advanced breast cancer. Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):787-92. Epub 2010 Jul 7.
Parsons CM, Muilenburg D, Bowles TL, Virudachalam S, Bold RJ. The role of Akt activation in the response to chemotherapy in pancreatic cancer. Anticancer Res. 2010 Sep;30(9):3279-89.